Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
NCT ID: NCT02731911
Last Updated: 2019-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
202 participants
OBSERVATIONAL
2016-04-29
2018-10-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
NCT03953807
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
NCT02188173
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
NCT01673191
Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.
NCT02121197
Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)
NCT03003416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ozurdex® (dexamethasone intravitreal implant)
Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
dexamethasone intravitreal implant
Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexamethasone intravitreal implant
Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Macular oedema due to DME
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. George Labib
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina and Macula Specialists,Hurstville
Hurtsville, New South Wales, Australia
Retina Associates
Liverpool, New South Wales, Australia
Retina and Macula Specialists, Miranda
Miranda, New South Wales, Australia
Eye Doctors Mona Vale
Mona Vale, New South Wales, Australia
Marsden Eye Clinic
Parramatta, New South Wales, Australia
Retina & Vitreous Centre Strathfield
Strathfield, New South Wales, Australia
Strathfield Retina
Strathfield, New South Wales, Australia
Retina & Vitreous Centre City
Sydney, New South Wales, Australia
Sydney Eye and Retina Clinic
Sydney, New South Wales, Australia
Sydney Eye Hospital/Macular Diseases Centre
Sydney, New South Wales, Australia
Sydney West Retina
Westmead, New South Wales, Australia
Terrace Eye Centre
Brisbane, Queensland, Australia
Caboolture Eye Surgery
Caboolture, Queensland, Australia
Peninsula Eye Hospital
Redcliffe, Queensland, Australia
The Qld Eye Institute
South Brisbane, Queensland, Australia
Adelaide Eye & Retina Centre
Adelaide, South Australia, Australia
Department of Opthalmology, Royal Adelaide Hospital
Adelaide, South Australia, Australia
Hobart Eye Surgeons
Hobart, Tasmania, Australia
Tasmanian Eye Institute
Launceston, Tasmania, Australia
Essendon Retina
Essendon, Victoria, Australia
Victoria Parade Eye Consultants
Fitzroy, Victoria, Australia
Vision Eye Institute
Footscry, Victoria, Australia
Lions Eye Institute
Nedlands, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mitchell P, Arnold J, Fraser-Bell S, Kang HK, Chang AA, Tainton J, Simonyi S. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study. BMJ Open Ophthalmol. 2023 Aug;8(1):e001224. doi: 10.1136/bmjophth-2022-001224.
Fraser-Bell S, Kang HK, Mitchell P, Arnold JJ, Tainton J, Simonyi S. Dexamethasone intravitreal implant in treatment-naive diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. Br J Ophthalmol. 2023 Jan;107(1):72-78. doi: 10.1136/bjophthalmol-2021-319070. Epub 2021 Aug 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMO-AP-EYE-0438
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.